Overview

Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Diabetic Macular Edema (BRDME)

Status:
Unknown status

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The primary objective is to demonstrate the non-inferiority of bevacizumab to ranibizumab in the treatment of patients with DME (OCT central area thickness > 275 μm) as determined by the change in best-corrected visual acuity (BCVA) in the study eye from baseline to month 6.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Prof. dr. R.O. Schlingemann

Collaborators:

Erasmus Medical Center
Free University Medical Center
Leiden University Medical Center
Radboud University
UMC Utrecht
University Medical Center Groningen

Treatments:

Bevacizumab
Ranibizumab